jupiter - I was unable to confirm your number of 17 patients on SGLT2's in the BoM trial when I went through the presentation. All of the % of patients were from the gross number of patients aside from your 6% of SGLT2 patients. So if you took 6% of 2425 it would be 146 patient virsus the 17 that you referred to. I agree that this is still a small number in totallity but still 8.5X's the 17 that you are using. The presentation did not give a number of CKD patients as it did in all other instances, just that %. It has always been my understanding that the number of patients on SGLT2's was around 150. I can not tell you where I saw that but it is consistant with 6% of the total number of patients in the BoM trial.

From the presentation by Dr KZ on the right: 

CKD patients had a longer mean duration of diabetes (11.3 vs. 8.2 years, P<0.001) and were less likely to be treated with metformin (69% vs. 84%, P<0.001) and SGLT2 inhibitors (6% vs. 13%, P=0.001). 

tada